<DOC>
	<DOCNO>NCT01699113</DOCNO>
	<brief_summary>The primary objective find healthy subject : - YF476 prevent ECL-cell hyperplasia induce repeated dos rabeprazole - proton pump inhibitor ; - YF476 also prevent rebound hyperacidity stop rabeprazole ; - YF476 cause neither ECL-cell hyperplasia repeat dos rebound hyperacidity stop YF476 . The secondary objective : - ass safety tolerability YF476 , alone combination rabeprazole ; - compare effect YF476 , alone combination rabeprazole , serum gastrin plasma CgA SST ; - ass pharmacokinetic interaction YF476 rabeprazole ; - ass pharmacokinetics repeat dos YF476 ; - study metabolism YF476 .</brief_summary>
	<brief_title>Effects YF476 Rabeprazole Gastric Function</brief_title>
	<detailed_description>We want know YF476 prevent ECL-cell hyperplasia induce PPI , rebound hyperacidity PPI withdrawal , man , rat . A positive result would support study assess combination YF476 PPI good way treat patient peptic ulcer disease GORD PPI alone . Equally , want know YF476 inhibits gastric acid secretion also cause ECL-cell hyperplasia rebound hyperacidity withdrawal . A positive result would support study assess YF476 alone alternative perhaps well treatment patient peptic ulcer disease GORD PPI alone . The study design important . We need ask several question . First , PPI use ? Omeprazole study PPI , probably still widely use PPI clinic . A disadvantage omeprazole metabolism affect genetic polymorphism . Studies human liver microsome vitro ( Yamazaki et al 1997 ) show omeprazole metabolise 5-hydroxylation ( catalysed CYP2C19 , less extent CYP3A4 ) sulphoxidation ( catalysed CYP3A4 ) . YF476 inhibits CYP3A4/5 vitro ; n't know relevant vivo . CYP2C19 3 genotype : homozygous extensive metabolisers , high enzymatic activity ; heterozygous extensive metabolisers , moderate enzymatic activity ; poor metabolisers , markedly impaired enzymatic activity . Consequently , CYP2C19 homozygous extensive metabolisers , acid suppression omeprazole reduce compare heterozygous poor metabolisers ( Shirai et al 2001 ) . Homozygous extensive metabolisers comprise 70 % European USA population 30 % Asian population . Recently , new CYP2C19 gene variant cause ultrarapid metabolism omeprazole identified 18 % Swedes ( Sim et al 2006 ) . So , use omeprazole , genotype subject CYP2C19 . Ideally , stratify allocation treatment , try avoid confound result . But , unlikely able get genotyping result quickly enough screen make stratification practical . Rabeprazole , unlike omeprazole , metabolise mainly via non-enzymatic pathway minor CYP2C19 CYP3A4 involvement . Therefore , acid suppression rabeprazole less affected CYP2C19 genotype ( Shirai et al 2001 ; Miura et al 2006 ) , one reason use rabeprazole instead omeprazole . Omeprazole rabeprazole off-patent , combination product YF476 either PPI possible . Second , dose PPI use , long ? The dose PPI one clinically relevant . If choice PPI omeprazole , dose 40 mg daily , 20 mg -- standard clinical dose -- less effective recommended dos PPI raise gastric pH ( Warrington et al 2006 ) . Rabeprazole 20 mg effective esomeprazole 20 mg study , another reason use rabeprazole ( Warrington et al 2005 ) . Taking everything account , decide use rabeprazole 20 mg daily study . The duration PPI dosing probably important choice PPI dose . The long duration dosing , likely show morphological change ECL-cell hyperplasia . But ethical consideration compliance issue mean compromise duration dose . The available evidence suggest 2 week long enough induce ECL-cell hyperplasia , whereas 8-12 week may long enough . So , 6 week seem reasonable compromise . Third , long stop PPI ass rebound hyperacidity ? Early study man fail show rebound hyperacidity stop omeprazole assessment do soon ( Prewett et al 1991 ) . PPIs non-competitive inhibitor proton pump , take day regenerate fully . The available evidence suggest 2 week PPI withdrawal long enough study rebound hyperacidity . Fourth , dose YF476 use ? Single repeat dos 100 mg daily well tolerate completely suppressed pentagastrin-stimulated increase gastric acid volume H+ content healthy subject . The toxicology toxicokinetic study support dose 100 mg daily 13 week . So , dose schedule 100 mg daily 6 week appropriate . Fifth , safe give PPI YF476 together ? No safety problem report rat give omeprazole YM022 , enantiomer YF476 , 13 week ( Nishida et al 1995 ) . Also , safety problem report omeprazole YF476 give rat 8 week ( Chen et al 2000 ) . However , whatever PPI use , assay blood concentration PPI YF476 ( Redrup et al 2002 ) start end dosing , l drug-drug interaction confound result outcome measure . Sixth , test gastric function ECL cell use compare treatment ? We study : plasma gastrin , assess degree hypergastrinaemia ; plasma CgA , marker ECL-cell hyperplasia ; plasma SST , marker D-cell activity ; pentagastrin-stimulated increase gastric acid volume H+ content , 24-hour ambulatory pH , compare anti-secretory response stop treatment ; gastric biopsy , assess change ECL-cell histology enzyme ; dyspepsia symptom , assess occurrence symptomatic rebound hyperacidity stop treatment . Seventh , study crossover parallel-group design ? In healthy subject , crossover study often ideal design . Comparisons make within rather subject , reduces variability result . But , crossover design practical give long dosage period demand procedure . By use rabeprazole , avoid potential problem between-subject difference attributable CYP2C19 genetic polymorphism . So , parallel-group design 3 group subject randomise either YF476 , rabeprazole , combination YF476 rabeprazole , sensible solution . Eighth , identical treatment placebo group ? We over-encapsulate treatment make identical study double blind design . Ideally , placebo group , study double blind design method mostly objective , placebo group essential . Finally , use patient healthy subject ? Healthy subject patient peptic ulcer disease GORD develop hypergastrinaemia ECL-cell hyperplasia repeat dose PPI , rebound hyperacidity stop PPI . Nevertheless , study best do healthy subject likely comply demand study procedure , homogeneous , robust , medication . The YF476 reproductive toxicology study justify include woman risk pregnancy . However , H pylori-positive subject exclude . In recent UK community study , 15 % people H pylori-positive ( Lane et al 2006 ) .</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Men woman , deem healthy basis clinical history , physical examination , ECG safety test blood urine ; able give fullyinformed , write consent . Women pregnant , lactate use steroid contraceptive . Clinically relevant abnormal history , physical finding , ECG , laboratory value pretrial screening assessment could interfere objective trial safety subject . Presence acute chronic illness history chronic illness sufficient invalidate subject 's participation trial make unnecessarily hazardous . Impaired endocrine , thyroid , hepatic , respiratory renal function , diabetes mellitus , coronary heart disease , history psychotic mental illness . Evidence high serum gastrin screen achlorhydria baseline . Presence history severe adverse reaction drug . Use prescription medicine antacid 28 day trial use overthecounter medication , exception paracetamol , 7 day trial . Participation trial new drug substance prescription medicine within previous 3 month . Presence history drug alcohol abuse , intake 28 unit alcohol weekly ( men ) 21 unit alcohol weekly ( woman ) . Blood pressure heart rate supine position screen examination outside range 90160 mm Hg systolic , 4095 mm Hg diastolic ; heart rate 40_100 beats/min . Possibility subject cooperating requirement protocol . Evidence drug abuse urine testing . Positive test hepatitis B , hepatitis C , HIV1 HIV2 . Loss &gt; 400 mL blood , e.g . blood donation , 3 month trial . Objection General Practitioner ( GP ) subject enter trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>YF476</keyword>
	<keyword>gastrin receptor antagonist</keyword>
	<keyword>gastric pH</keyword>
	<keyword>gastrin</keyword>
	<keyword>rabeprazole</keyword>
	<keyword>proton-pump inhibitor</keyword>
	<keyword>gastric function</keyword>
	<keyword>healthy subject</keyword>
</DOC>